Medigen Biotechnology (3176) — Cash Flow-to-Debt Ratio
Medigen Biotechnology (3176) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of NT$-18.91 Million could theoretically repay 0% of its total liabilities (NT$1.45 Billion) in one year. See Medigen Biotechnology (3176) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medigen Biotechnology Cash Flow-to-Debt Ratio (2003–2024)
Historical debt coverage capacity for Medigen Biotechnology across 12 annual periods. Also explore 3176 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Medigen Biotechnology (2003–2024)
Year-by-year debt coverage analysis for Medigen Biotechnology. For market capitalisation and broader financial context, see Medigen Biotechnology (3176) total market value.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | NT$37.92 Million | NT$1.67 Billion | ▲ +114.1% |
| 2023 | -0.16x | NT$-569.40 Million | NT$3.53 Billion | ▲ +49.8% |
| 2022 | -0.32x | NT$-1.13 Billion | NT$3.51 Billion | ▼ -210.1% |
| 2021 | 0.29x | NT$517.45 Million | NT$1.77 Billion | ▲ +171.8% |
| 2020 | -0.41x | NT$-671.38 Million | NT$1.65 Billion | ▼ -55.4% |
| 2019 | -0.26x | NT$-560.17 Million | NT$2.14 Billion | ▲ +18.3% |
| 2018 | -0.32x | NT$-529.82 Million | NT$1.66 Billion | ▼ -18.6% |
| 2017 | -0.27x | NT$-455.62 Million | NT$1.69 Billion | ▲ +26.1% |
| 2016 | -0.36x | NT$-468.61 Million | NT$1.28 Billion | ▼ -227.8% |
| 2015 | 0.29x | NT$294.18 Million | NT$1.03 Billion | ▼ -81.7% |
| 2005 | 1.56x | NT$80.72 Million | NT$51.78 Million | ▼ -61.5% |
| 2003 | 4.04x | NT$445.46 Million | NT$110.16 Million | — |